Literature DB >> 17101452

Brain iron metabolism.

Tracey A Rouault1, Sharon Cooperman.   

Abstract

Brain iron uptake is regulated by the expression of transferrin receptor 1 in endothelial cells of the blood-brain barrier. Transferrin-bound iron in the systemic circulation is endocytosed by brain endothelial cells, and elemental iron is released to brain interstitial fluid, likely by the iron exporter, ferroportin. Transferrin synthesized by oligodendrocytes in the brain binds much of the iron that traverses the blood-brain barrier after oxidation of the iron, most likely by a glycophosphosinositide-linked ceruloplasmin found in astrocytic foot processes that ensheathe brain endothelial cells. Neurons acquire iron from diferric transferrin, but it is less clear how glial cells acquire iron. In aging mammals, iron accumulates in the basal ganglia, and iron accumulation is believed to contribute to neurodegenerative diseases, including Parkinson and Alzheimer disease. Here we consider the possibility that iron accumulations, which are often thought to facilitate free radical generation and oxidative damage, may contain insoluble iron that is unavailable for cellular use, and the pathology associated with iron accumulations may result from functional iron deficiency in some diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17101452     DOI: 10.1016/j.spen.2006.08.002

Source DB:  PubMed          Journal:  Semin Pediatr Neurol        ISSN: 1071-9091            Impact factor:   1.636


  104 in total

1.  PKA modulates iron trafficking in the striatum via small GTPase, Rhes.

Authors:  Bo-Ran Choi; Sookhee Bang; Yong Chen; Jaime H Cheah; Sangwon F Kim
Journal:  Neuroscience       Date:  2013-08-30       Impact factor: 3.590

Review 2.  Iron and mechanisms of emotional behavior.

Authors:  Jonghan Kim; Marianne Wessling-Resnick
Journal:  J Nutr Biochem       Date:  2014-08-02       Impact factor: 6.048

3.  Cerebral microbleeds in the elderly: a pathological analysis.

Authors:  Mark Fisher; Samuel French; Ping Ji; Ronald C Kim
Journal:  Stroke       Date:  2010-10-28       Impact factor: 7.914

4.  Iron is essential for oligodendrocyte genesis following intraspinal macrophage activation.

Authors:  David L Schonberg; Dana M McTigue
Journal:  Exp Neurol       Date:  2009-04-15       Impact factor: 5.330

Review 5.  Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.

Authors:  Carmen Noelker; Harald Hampel; Richard Dodel
Journal:  Mol Diagn Ther       Date:  2011-04-01       Impact factor: 4.074

Review 6.  Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim.

Authors:  Orly Weinreb; Silvia Mandel; Orit Bar-Am; Tamar Amit
Journal:  J Neural Transm (Vienna)       Date:  2011-03-01       Impact factor: 3.575

7.  Iron, zinc and copper in the Alzheimer's disease brain: a quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion.

Authors:  Matthew Schrag; Claudius Mueller; Udochukwu Oyoyo; Mark A Smith; Wolff M Kirsch
Journal:  Prog Neurobiol       Date:  2011-05-11       Impact factor: 11.685

8.  Dysregulated iron metabolism in the choroid plexus in fragile X-associated tremor/ataxia syndrome.

Authors:  Jeanelle Ariza; Craig Steward; Flora Rueckert; Matt Widdison; Robert Coffman; Atiyeh Afjei; Stephen C Noctor; Randi Hagerman; Paul Hagerman; Verónica Martínez-Cerdeño
Journal:  Brain Res       Date:  2014-12-09       Impact factor: 3.252

9.  Ferroportin is a manganese-responsive protein that decreases manganese cytotoxicity and accumulation.

Authors:  Zhaobao Yin; Haiyan Jiang; Eun-Sook Y Lee; Mingwei Ni; Keith M Erikson; Dejan Milatovic; Aaron B Bowman; Michael Aschner
Journal:  J Neurochem       Date:  2009-12-09       Impact factor: 5.372

10.  Iron chelation protects the retinal pigment epithelial cell line ARPE-19 against cell death triggered by diverse stimuli.

Authors:  Nina Lukinova; Jared Iacovelli; Tzvete Dentchev; Natalie Wolkow; Allan Hunter; Defne Amado; Gui-Shuang Ying; Janet R Sparrow; Joshua L Dunaief
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-01-31       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.